Clinical trial

Preoperative Paravertebral Block in Cancer Surgery of the Lung: ParaSOL a Prospective Randomized Controlled Clinical Trial

Name
244680
Description
The investigators aim to determine whether ultrasound-guided preemptive paravertebral blockade (PVB) local anaesthetic (pre-PVB LA), administered in addition to the post-operative PVB (post-PVB) local anaesthetic (LA) infusion, reduces acute postoperative pain, opioid requirement, chronic pain, and improves surgical recovery, in thoracoscopic surgery for lung cancer.
Trial arms
Trial start
2019-02-01
Estimated PCD
2024-12-01
Trial end
2024-12-31
Status
Recruiting
Phase
Early phase I
Treatment
Levo-Bupivacaine Hydrochloride (HCl) 0.5 % in 20mL Injection
As per arm description
Arms:
Pre-PVB with 0.5% Levo-bupivacaine
0.9% Sodium Chloride 20mL Injection
As per arm description
Arms:
Pre-PVB with saline
Size
100
Primary endpoint
Moderate-to-severe pain Numerical Rating Scale (NRS) >/=3
1 day
Eligibility criteria
Inclusion Criteria: * Elective radical primary lung cancer VATS surgery for single lobectomy * American Society of Anesthesiology (ASA) I-III * Age ≥18 Exclusion Criteria: * Planned open thoracotomy, wedge resection, bilobectomy, pneumonectomy, chest wall resection or total pleurectomy * Local anaesthetic or opioid allergy * Coagulation disorders * Inability to comply with study questionnaire completion * Pre-existing pain in chest area or pre-existing pain conditions * Local infection/tumour at proposed PVB site * Previous lung surgery * Planned surgery within 3 months of the primary lung resection
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2', 'PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': "The study will be conducted at Guy's Hospital, London, United Kingdom (UK), a large tertiary thoracic centre for London, Sussex, Kent and Berkshire. In 2015, 459 lung cancer resection operations were performed; 8% of all lung cancer resections in England.\n\nCriteria for discontinuation/withdrawal or modifying allocated treatment:\n\n* Participant request to withdraw from the study.\n* Intraoperative identification of infection/tumour in paravertebral space\n\nPatient recruitment Eligible patients will be identified in the catchment outpatient clinics 4-6 weeks before surgery. The participant information sheet (PIS) will be introduced in the standard surgical booklet given by the surgeon. At the preoperative assessment clinic 2-3 weeks before surgery, a face-to-face discussion with the research nurse will support the PIS; the opportunity to ask any questions and contact a PPI (Patient and Public Involvement) representative and will be given. Written informed consent will be obtained.", 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'maskingDescription': "Participants will be randomised on the day of surgery to the 'pre-PVB LA' or 'pre-PVB saline' arm, by a study investigator, with a 1:1 randomisation ratio using 'Sealed Envelope' (www.sealedenvelope.com) online software. Each subject will receive a unique randomization code in an envelope that will only be opened during the preparation of the pre-PVB injectate.\n\nA non-blinded research nurse, will prepare the pre-PVB injectate in a standard syringe according to the allocation, labelled by participant number, in a theatre location concealed from the operating room and staff.\n\nThe anaesthetist, the surgeon and theatre team, recovery staff, and the researchers performing all the outcome assessments will be separate and blinded to the group allocation. The PVB catheter will be taped as normal before connecting the post-PVB LA infusion pump.\n\nWe have elected to perform an interventional placebo intervention as opposed to a sham control to minimize observer bias.", 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 100, 'type': 'ESTIMATED'}}
Updated at
2024-03-29

1 organization

2 products

5 indications

Indication
Anesthesia
Indication
Local